A year-old woman presents to the emergency department following two weeks of progressive dyspnea and fatigue, and a new rash. Her medical history is significant for stage 2 chronic kidney disease, coronary artery disease, and diabetes. Physical examination results are within normal limits, except for skin pallor and a petechial rash on the lower extremities bilaterally. A bone marrow biopsy reveals a hypercellular marrow with 22 percent blasts, consistent with a diagnosis of acute myeloid leukemia AML. Flow cytometry demonstrates CD33 negativity, and classic cytogenetic analysis revealed a normal karyotype. A pre-treatment echocardiogram is performed and is notable for mild global systolic dysfunction and a left-ventricular ejection fraction of 45 percent.
A case of simultaneous occurrence of acute myeloid leukemia and multiple myeloma
Case Study: New Therapies for Acute Myeloid Leukemia - zazoom.info
Acute myeloid leukemia AML is a cancer of the myeloid line of blood cells , characterized by the rapid growth of abnormal cells that build up in the bone marrow and blood and interfere with normal blood cell production. Risk factors include smoking , previous chemotherapy or radiation therapy , myelodysplastic syndrome , and exposure to the chemical benzene. AML typically is initially treated with chemotherapy , with the aim of inducing remission. In , AML affected about one million people and resulted in , deaths globally. Most signs and symptoms of AML are caused by the replacement of normal blood cells with leukemic cells.
Case Study: New Therapies for Acute Myeloid Leukemia
Background: Although the occurrence of acute myeloid leukemia AML after chemotherapy for multiple myeloma MM is common in clinical settings, the simultaneous occurrence of these malignancies in patients without previous exposure to chemotherapy is a rare event. Etiology, disease management, and clinical treatment remain unclear for this particular occurrence. To the best of our knowledge, this study is the first to report a case of simultaneous presentation of AML and MM after exposure to ultraviolet irradiation. Fluorescent in situ hybridization analysis of immunomagnetically separated abnormal plasma cells showed abnormal expression of the amplified RB-1, TP53, and CDKN2C 1p
We hereby describe what we believe to be the first reported case of t 14; 15 q32; q13 associated with acute myeloid leukemia AML. She presented 19 months after diagnosis with relapsed disease. Of note, at relapse cytogenetic analysis revealed t 14; 15 q32; q13 , while FLT-3 analysis showed a codon D mutation no ITD mutation was detected. She proved refractory to the initial clofarabine-based regimen, so FLAG-idarubicin then was used. She continued to have persistent disease, and she was discharged on best supportive care.